Company Co-founder Venkat Shastri to Remain Active in Advisory Role
CARLSBAD, CA, July 9, 2024 – ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced the board’s appointment of Chad Holland as the company’s new president and CEO. The appointment comes after Venkat Shastri, company co-founder and former CEO, chose to step aside to take on an advisory role.
“ALZpath is at a pivotal moment of growth,” said Jerre Stead, board chair of ALZpath. “We are excited about our success to date, and we are tremendously grateful to Venkat, under whose leadership our company has reached this point. With Chad as our president and CEO, the support of our board and scientific advisory board, and Venkat’s ongoing counsel, we will continue our successful trajectory, helping to transform the Alzheimer’s care continuum.”
Holland brings a deep skillset in commercialization, business development, and fundraising, perfectly positioning him to accelerate the company’s growth. “We will continue with the successful execution of our pTau217 antibody as the premier reagent for use across diagnostic and research platforms to dramatically improve the outlook for Alzheimer’s patients,” Holland said.
“Looking forward, we will leverage the deep expertise of our team to anticipate and build toward what’s next. This is an incredible time in neurology and neuroscience as we gain new insights to tackle neurodegenerative disorders that until now have been unsolvable.”